BioCentury
ARTICLE | Clinical News

Titan begins Phase II

April 10, 2001 7:00 AM UTC

TTP began a Phase II study of a combination of its CeaVac and TriAb monoclonal antibodies to treat non-small cell lung cancer (NSCLC). The study will assess the safety and preliminary efficacy of the ...